Australia's most trusted
source of pharma news
Friday, 04 July 2025
Posted 4 July 2025 PM
Regeneron and Bayer have moved to protect an almost half-a-billion dollar Australian market from biosimilar competition, taking Sandoz to court alleging patent infringement.
The two pharmas commenced proceedings against Sandoz last month, for allegedly threatening to infringe on a patent protecting eye blockbuster Eylea, which Bayer has the rights to market in Australia.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.